Meeting
2024 ASCO Annual Meeting
Targeting rare variants of a pan-cancer target: The landscape of BRAF non-v600 mutations and BRAF fusions from 172,005 adult patients with cancer.
Authors
Niamh Coleman
Trinity St. James's Cancer Institute, Dublin, Ireland
Niamh Coleman , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3113)
DOI
10.1200/JCO.2024.42.16_suppl.3113
Abstract #
3113
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
First Author: Johanna C. Bendell
Poster
2022 ASCO Annual Meeting
Characterizing the genomic landscape of PIK3CA alterations from 121,221 adult patients with cancer: The next tissue-agnostic target?
First Author: Niamh Coleman
Poster
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience.
First Author: Marta Padovan
Poster
2016 ASCO Annual Meeting
Dynamics of mutant BRAF V600E in free circulating DNA (fcDNA) of non-melanoma cancer patients (pts) in response to treatment with BRAF and MEK/EGFR inhibitors.
First Author: Morten Mau-Soerensen